Gregory KD, Chelmow D, Nelson HD, et al. Ann Intern Med. 2020;173:48-56. 32510990.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7326/ACPJ202011170-050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improving Adolescent and Young Adult Health Through Knowledge and Action on Gender-Based Violence.
J Adolesc Health
January 2025
Gender-based violence (GBV) refers to a specific form of interpersonal violence that is rooted in gender inequities and unequal distribution of power. GBV is defined as any type of violence, including physical, sexual, psychological, and economic, perpetrated against individual(s) based on actual or perceived gender, gender identity, gender expression, sex or sex characteristics, sexual orientation, or divergence from social norms on masculinity and femininity. Cisgender (cis) and transgender (trans) women and girls of all ages, including adolescents and young adults (AYAs) of ages 10-24 years, disproportionately experience GBV.
View Article and Find Full Text PDFA prospective study of the association between lifestyle and the risk of depressive symptoms.
J Affect Disord
January 2025
Department of Epidemiology, Fukushima Medical University School of Medicine, 1 Hikariga-oka, Fukushima 960-1295, Japan; Radiation Medical Science Center for the Fukushima Health Management Survey, Fukushima Medical University, 1 Hikariga-oka, Fukushima 960-1295, Japan. Electronic address:
Background: Few studies have prospectively, comprehensively, and by sex, examined the relationship between lifestyle and depressive symptoms. This study aimed to longitudinally examine which lifestyle factors are associated with depressive symptoms in a large cohort of Japanese participants stratified by sex.
Methods: Among 9087 office and community-based residents who attended a health measurement course at the Osaka Medical Center for Health Science and Promotion between 2001 and 2002, 6629 individuals (3962 men and 2667 women) without prior depressive symptoms were followed until the end of March 2012 to observe the associations between lifestyle factors and the development of new depressive symptoms.
Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder.
J Affect Disord
January 2025
Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA; Department of Medicine, Duke University, Durham, NC, USA; Duke Institute of Brain Sciences, Duke University, Durham, NC, USA. Electronic address:
Metabolomics provides powerful tools that can inform about heterogeneity in disease and response to treatments. In this exploratory study, we employed an electrochemistry-based targeted metabolomics platform to assess the metabolic effects of three randomly-assigned treatments: escitalopram, duloxetine, and Cognitive-Behavioral Therapy (CBT) in 163 treatment-naïve outpatients with major depressive disorder. Serum samples from baseline and 12 weeks post-treatment were analyzed using targeted liquid chromatography-electrochemistry for metabolites related to tryptophan, tyrosine metabolism and related pathways.
View Article and Find Full Text PDFAssessing the impact of e-cigarettes on human barrier systems: a systematic review.
Transl Res
January 2025
Occupational Medicine, Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy. Electronic address:
The use of e-cigarettes has grown rapidly in recent years, raising concerns about their impact on human health, particularly on critical physiological barriers such as the blood-brain barrier (BBB), alveolar-capillary barrier, and vascular systems. This systematic review evaluates the current literature on the effects of e-cigarette exposure on these barrier systems. E-cigarettes, regardless of nicotine content, have been shown to induce oxidative stress, inflammation, and disruption of tight junction proteins, leading to impaired barrier function.
View Article and Find Full Text PDFFinerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.
Lancet Diabetes Endocrinol
January 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Electronic address:
Background: Data on the effect of mineralocorticoid receptor antagonist therapy on HbA levels and new-onset diabetes are conflicting. We aimed to examine the effect of oral finerenone, compared with placebo, on incident diabetes in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) trial.
Methods: In this randomised, double-blind, placebo-controlled trial, 6001 participants with heart failure with New York Heart Association functional class II-IV, left ventricular ejection fraction 40% or higher, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomly assigned to finerenone or placebo, administered orally.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!